📊 EOLS Key Takeaways
Is Evolus, Inc. (EOLS) a Good Investment?
Evolus demonstrates healthy revenue growth (11.6% YoY) and strong gross margins (66.9%), indicating viable product demand and unit economics. However, the company faces critical financial distress: negative stockholders' equity (-$28.8M), unsustainable debt load ($156.4M vs $49.8M cash), negative operating cash flow (-$10.0M), and inability to cover interest expense from operations (interest coverage -1.5x), creating acute refinancing and solvency risk.
Evolus is showing solid top-line growth and healthy gross margins, which suggests its core product economics remain attractive. However, that revenue growth is not translating into operating profitability or cash generation, and the combination of recurring losses, negative free cash flow, high leverage, and negative equity materially weakens the fundamental picture. Until margin improvement and cash flow stabilization become clear, the business looks financially stretched rather than fundamentally strong.
Why Buy Evolus, Inc. Stock? EOLS Key Strengths
- Revenue growth of 11.6% YoY indicates sustained market demand for products
- Gross margin of 66.9% demonstrates strong product-level unit economics and pricing power
- Current ratio of 2.04x and cash position of $49.8M provide near-term liquidity buffer
- Revenue grew 11.6% year over year, indicating continued commercial demand
- Gross margin of 66.3% shows strong underlying product economics
- Current ratio of 1.90x and quick ratio of 1.54x indicate acceptable near-term liquidity
EOLS Stock Risks: Evolus, Inc. Investment Risks
- Negative stockholders' equity (-$28.8M) indicates technical insolvency and liabilities exceed total assets
- Debt burden of $156.4M with only $49.8M cash and negative operating cash flow creates imminent refinancing risk
- Negative operating (-$6.8M) and free cash flow (-$10.4M) demonstrates business is not self-sustaining at current scale
- Interest coverage ratio of -1.5x shows company cannot service debt obligations from operations
- Operating margin of -11.0% and net margin of -17.4% show the company is still structurally unprofitable
- Negative operating cash flow and free cash flow indicate growth is not yet self-funding
- Negative stockholders equity, $146.10M of long-term debt, and negative interest coverage point to elevated balance sheet risk
Key Metrics to Watch
- Time to operating profitability and path to positive operating cash flow
- Debt restructuring or reduction strategy and refinancing timeline
- Quarterly cash burn rate and runway to potential liquidity crisis
- Operating cash flow and free cash flow trend
- Operating margin improvement relative to revenue growth
Evolus, Inc. (EOLS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.04x current ratio provides a solid financial cushion.
EOLS Profit Margin, ROE & Profitability Analysis
EOLS vs Healthcare Sector: How Evolus, Inc. Compares
How Evolus, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Evolus, Inc. Stock Overvalued? EOLS Valuation Analysis 2026
Based on fundamental analysis, Evolus, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Evolus, Inc. Balance Sheet: EOLS Debt, Cash & Liquidity
EOLS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Evolus, Inc.'s revenue has grown significantly by 198% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.08 indicates the company is currently unprofitable.
EOLS Revenue Growth, EPS Growth & YoY Performance
EOLS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $68.5M | -$10.7M | $-0.16 |
| Q3 2025 | $61.1M | -$11.4M | $-0.24 |
| Q2 2025 | $66.9M | -$11.4M | $-0.18 |
| Q1 2025 | $59.3M | -$13.1M | $-0.22 |
| Q3 2024 | $50.0M | -$11.4M | $-0.30 |
| Q2 2024 | $49.3M | -$11.4M | $-0.18 |
| Q1 2024 | $41.7M | -$13.1M | $-0.22 |
| Q3 2023 | $33.9M | -$14.8M | $-0.30 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Evolus, Inc. Dividends, Buybacks & Capital Allocation
EOLS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Evolus, Inc. (CIK: 0001570562)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EOLS
What is the AI rating for EOLS?
Evolus, Inc. (EOLS) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EOLS's key strengths?
Claude: Revenue growth of 11.6% YoY indicates sustained market demand for products. Gross margin of 66.9% demonstrates strong product-level unit economics and pricing power. ChatGPT: Revenue grew 11.6% year over year, indicating continued commercial demand. Gross margin of 66.3% shows strong underlying product economics.
What are the risks of investing in EOLS?
Claude: Negative stockholders' equity (-$28.8M) indicates technical insolvency and liabilities exceed total assets. Debt burden of $156.4M with only $49.8M cash and negative operating cash flow creates imminent refinancing risk. ChatGPT: Operating margin of -11.0% and net margin of -17.4% show the company is still structurally unprofitable. Negative operating cash flow and free cash flow indicate growth is not yet self-funding.
What is EOLS's revenue and growth?
Evolus, Inc. reported revenue of $73.1M.
Does EOLS pay dividends?
Evolus, Inc. does not currently pay dividends.
Where can I find EOLS SEC filings?
Official SEC filings for Evolus, Inc. (CIK: 0001570562) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EOLS's EPS?
Evolus, Inc. has a diluted EPS of $-0.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EOLS a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Evolus, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EOLS stock overvalued or undervalued?
Valuation metrics for EOLS: ROE of N/A (sector avg: 15%), net margin of -14.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EOLS stock in 2026?
Our dual AI analysis gives Evolus, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EOLS's free cash flow?
Evolus, Inc.'s operating cash flow is $-10.0M, with capital expenditures of $415.0K. FCF margin is -14.2%.
How does EOLS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -14.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.04 (avg: 2).